Abstract
Sir, Your correspondents' main assertion is that our estimate of lead time in breast screening is too large due to the inclusion of all breast cancer cases in its estimation and that as a consequence our estimate of overdiagnosis is too small. First, we explicitly stated that our excess incidence of 39% was not claimed to estimate overdiagnosis, so they are mistaken on that count. Secondly, we do not find their argument about lead time persuasive, as our estimate of 2.4 years is consistent with sojourn time estimates from studies that used heterogeneity models allowing for some cancers never to progress (Duffy et al, 2005; Olsen et al, 2006). Your correspondents' preferred approach (Zahl et al, 2004) of comparing the rise in incidence in a screened age group with the drop in incidence at higher ages is similarly unconvincing because, as was pointed out in the British Medical Journal rapid response columns at the time, there was inaccurate specification of screened age groups, insufficient time for the subsequent drop in incidence to be observed and insufficient attention was paid to other factors (notably hormone replacement therapy use). We are also sceptical about their assertions concerning overdiagnosis in the Malmo Trial. They cite screening in the control group but fail to consider continued voluntary screening in the study group after invitations had ceased. Whether it is convenient or not for us and for your correspondents, methodological complexities such as lead time are highly influential in the observed incidence during a screening programme. Failure to take these into account leads to implausibly high estimates of the order asserted by your correspondents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.